Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review. - Wikidata - wikimedia - TriplyDB

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.

http://www.wikidata.org/entity/Q34042148

about

Resource consumption and costs of treatment in patients with type 1 diabetes under intensified conventional therapy under German real-life conditions.Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus.

P2860

Q37406036-AB2A6F0A-0A2F-4768-8714-C01A0D1503D7 Q38983622-5A515840-FFD1-4517-8B51-CCAF234E2F99

P2860

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.

http://www.wikidata.org/entity/Q34042148

description

2011 nî lūn-bûn

@nan

2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Health economic evaluations co ...... diabetes: a systematic review.

@ast

Health economic evaluations co ...... diabetes: a systematic review.

@en

Health economic evaluations co ...... diabetes: a systematic review.

@nl

type

label

Health economic evaluations co ...... diabetes: a systematic review.

@ast

Health economic evaluations co ...... diabetes: a systematic review.

@en

Health economic evaluations co ...... diabetes: a systematic review.

@nl

prefLabel

Health economic evaluations co ...... diabetes: a systematic review.

@ast

Health economic evaluations co ...... diabetes: a systematic review.

@en

Health economic evaluations co ...... diabetes: a systematic review.

@nl

P1433

Q34042148-A9538784-22FC-4FDA-B26B-F316EF1634BA

P1476

Q34042148-C6ADE389-14B7-4889-983D-C981802C5468

P2093

Q34042148-559C7C59-76C2-47AA-A49D-AE66523D2FCA

Q34042148-70B90824-D7F9-496A-966B-099C9E5A87E8

Q34042148-BC0D5DD5-1E20-4C9F-B5DF-E9C454107C5A

Q34042148-D0C459CC-E95F-4A8B-B44B-122CF3C466BE

P2860

Q34042148-197A502E-C8BD-4CBB-A764-90C9D82EE9DD

Q34042148-1FD1893F-CD31-410E-A628-579DADE67B7D

Q34042148-25A966CA-72CE-4388-93E9-81BDA9523706

Q34042148-30DC0F7C-3B52-42A1-B345-F5A127291682

Q34042148-3983F915-8009-47C7-88A0-FDE97C2A154B

Q34042148-6376151E-3E4A-4B67-8DED-B25AB2E22FC8

Q34042148-63A3C0FB-A08D-4004-BC70-CBF887DB59EF

Q34042148-69AC58CC-20EC-4235-83D2-E2029067C69B

Q34042148-789BBD8E-A483-4F74-85C8-14141E6BB6CA

Q34042148-8137C343-D92A-4376-98F2-59A6BAB777DF

P2888

Q34042148-75480EF6-B509-44A9-A69B-65D6E776DE3F

P304

Q34042148-BD590DA5-DE19-4CDE-8C44-D759960367C8

P31

Q34042148-7E5BE1CE-9650-45DD-9A08-21F59C0F595B

P356

Q34042148-6E1C1C7E-CCBD-4E96-9444-9BA5BE8E853B

P433

Q34042148-6DB0AF40-D307-4D8E-858C-66E57BEFA624

P478

Q34042148-0667013F-1514-4471-B0E5-CC33161BE0F7

P577

Q34042148-B9A6021F-1169-42F1-ABB8-75B3524B2B30

P5875

Q34042148-F1A5942F-3B01-4DB7-A233-881E11A22CF5

P6179

Q34042148-30B8F151-C56A-49BB-B446-FABAD106421B

P698

Q34042148-B63BA0F1-88C7-4C2A-ADF7-AB209BC22996

P921

Q34042148-85C12230-8BEF-49C7-ACDE-313F5C7F932B

Q34042148-AFDA538A-C7E4-4149-9E19-1E914A9CAB74

P932

Q34042148-FB9DF105-9538-4165-B224-7D97ED6E9524

P356

P1433

Cost Effectiveness and Resource Allocation

P1476

Health economic evaluations co ...... diabetes: a systematic review.

@en

P2093

Ernst-Günther Hagenmeyer

http://www.w3.org/2001/XMLSchema#string

Franz-Werner Dippel

http://www.w3.org/2001/XMLSchema#string

Katharina C Koltermann

http://www.w3.org/2001/XMLSchema#string

Peter K Schädlich

http://www.w3.org/2001/XMLSchema#string

P2860

Intermediate acting versus long acting insulin for type 1 diabetes mellitus

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration

Cost-effectiveness of insulin analogues for diabetes mellitus.

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value.

Guidelines for computer modeling of diabetes and its complications.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.

Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

P2888

P304

15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1478-7547-9-15

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51705276

http://www.w3.org/2001/XMLSchema#string

P6179

1015426120

http://www.w3.org/2001/XMLSchema#string

P698

21978524

http://www.w3.org/2001/XMLSchema#string

P921

type-1 diabetes

P932

3200149

http://www.w3.org/2001/XMLSchema#string